Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

NCT05432596 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: ATI-1777 2.0% w/w
DRUG: ATI-1777 1.0% w/w
DRUG: ATI-1777 0.5% w/w
DRUG: Vehicle

Sponsor

Aclaris Therapeutics, Inc.